Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

NCT04131738 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Graft-versus-host-disease
Graft Vs Host Disease

Interventions

DRUG: Baricitinib

Sponsor

Washington University School of Medicine